Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In forty-five children the hypoxanthine concentration in cerebrospinal fluid (CSF) was measured (fifty-two samples). In newborn infants (nineteen patients) the hypoxanthine levels were higher in patients with clinical conditions associated with hypoxia (idiopathic respiratory distress syndrome, asphyxia, apneic attacks) than in patients without clinical hypoxia (P less than 0.01). In hypoxic patients the hypoxanthine concentration varied between 5 and 28 mu mol/l. In children outside the neonatal period the hypoxanthine concentration in CSF varied considerably in different diseases. High levels were registered in meningitis prior to treatment, febrile convulsions and in lymphoblastic leukaemia, probably reflecting tissue hypoxia and an increased tissue catabolism.
...
PMID:Hypoxanthine in cerebrospinal fluid in children. 70 28

Splenomegaly associated with myelodysplastic disorders in children may be massive and can result in pancytopenia, abdominal discomfort, and respiratory distress. When these symptoms cannot be relieved by nonsurgical means, splenectomy may be indicated. Under such conditions, surgical splenectomy carries increased risks, as the thrombocytopenia is difficult to correct secondary to splenic sequestration. Additionally, the surgical anatomy is often distorted secondary to the massive spleen and dissection can be difficult. These factors can lead to uncontrollable hemorrhage. In an attempt to decrease intraoperative blood loss, the authors successfully performed preoperative splenic artery embolization in 11 of 12 children (age range, 1-11 years) with pancytopenia due to hypersplenism. Hypersplenism requiring surgical splenectomy was due to leukemia (n = 9), myelodysplastic syndrome (n = 1), immune thrombocytopenia (n = 1), and osteopetrosis (n = 1). Embolization was performed under general anesthesia, prior to surgery, with gelatin sponge particles alone, Gianturco coils alone, or a combination of polyvinyl alcohol sponge particles and Gianturco coils. Embolization allowed for safe surgical splenectomy.
...
PMID:Preoperative embolization of the spleen in children with hypersplenism. 144 26

Acute respiratory failure developed in two patients with hyperleukocytic acute myelomonocytic leukemia with abnormal marrow eosinophils within 1 to 3 days after the beginning of high-dose induction chemotherapy. The presence of moderate pulmonary leukostasis before chemotherapy initiation, the simultaneous occurrence of an acute tumor lysis syndrome, the lack of evidence of any other cause of respiratory distress, and the clinical evolution lead the authors to attribute pulmonary injury to lysis of resident leukemic cells. The responsibility of eosinophilic cellular constituents for the diffuse alveolar damage is discussed.
...
PMID:Acute lysis pneumopathy after chemotherapy for acute myelomonocytic leukemia with abnormal marrow eosinophils. 154 Aug 73

Pulmonary leukostasis is a serious, almost always fatal, complication usually reported to occur in patients with acute granulocytic leukemias when the peripheral white blood cells exceed 50,000/mm3. We report a clinicopathologic study of 16 leukemic patients with pulmonary leukostasis and with less than 50,000/mm3 circulating leukocytes. The results demonstrated that hyperleukocytosis per se cannot be the cause of pulmonary leukostasis, but that other factors, such as the presence of circulating blasts and the affinity of neoplastic cells for the pulmonary endothelium, may be related to the development of acute respiratory distress in patients with leukemia.
...
PMID:Pulmonary leukostasis without hyperleukocytosis: a clinicopathologic study of 16 cases. 156 43

Three children, two boys and one girl, with Down syndrome (DS) who presented with preleukemia and loss of all or part of chromosome 7 were studied. Initial presentation, with cytopenias and less than 25% blasts in the bone marrow, was between 13 and 30 months of age. Progression to acute nonlymphocytic leukemia occurred 1-8 months after initial presentation. The morphologic type was megakaryoblastic in two, and undifferentiated in one. Two children achieved remission with intensive therapy, and one continues in remission off therapy; the other child died in remission of accidental causes. The third child died of respiratory distress and leukemia after no intervention was chosen. These cases represent the first examples of chromosome 7 abnormalities associated with DS and leukemia, and suggest differences from the "monosomy 7" syndrome seen in children without DS.
...
PMID:Chromosome 7 abnormalities in children with Down syndrome and preleukemia. 182 46

A follow-up was carried out on twenty-two children (thirteen of whom were newborn) who had been treated with porcine surfactant (Curosurf) for respiratory distress syndrome. All the infants were enrolled in the follow-up at different times after surfactant replacement to evaluate the clinical status and the incidence (if any) of respiratory disease, adverse drug effects and allergic conditions. Twelve of the twenty-two children treated completed the follow-up. Seven prematurely-born children died of endocranial haemorrhage; two children died of malignant development of the basal pathology (leukaemia). Treatment with pig surfactant appears to cause no allergic side effects. Skin and laboratory tests performed were negative.
...
PMID:Follow-up on infants treated with porcine surfactant replacement for severe neonatal and infant respiratory distress syndrome: antigenic reactivity evaluation. 184 Oct 41

Hyperleukocytosis in leukemia challenges physicians and nurses to provide swift and aggressive care to the patient so that complications from leukostasis are avoided. It is therefore prudent for nurses to recognize patients at risk for hyperleukocytosis. Prevention of complications is the key because once pulmonary and central nervous system symptoms arise the probability for reversal becomes uncertain. The major role of nurses caring for patients with hyperleukocytosis is to provide baseline assessment of pulmonary and neurological function, with continuous follow-up assessment to detect early signs and symptoms of organ dysfunction. Once complications from hyperleukocytosis are apparent, nursing interventions are aimed at easing respiratory distress, minimizing increases in intercranial pressure, and providing emotional support for the patient and his family.
...
PMID:Hyperleukocytosis in leukemia. 184 87

Several studies have been performed in the last ten-years on the biochemical and physiopathologic properties of angiotensin-converting enzyme (ACE). Human lung and kidney are a rich source of ACE and the enzyme is bound to the plasma-membrane of vascular endothelial cells; however, the small intestine and the choroid plexus are also particularly rich in ACE, where it is concentrated on the surface of cuboidal epithelial cells facing the cerebrospinal fluid. The ACE is a glycoprotein with a molecular weight of 150,000 daltons and it cleaves C-terminal dipeptides of several oligo-peptides, including angiotensin I and bradykinin. It catalyzes conversion of angiotensin I to angiotensin II and induces inactivation of bradykinin. Synthetic acylated tripeptides such as radiolabelled hippuryl-histidyl-leucine and hippuryl-glycyl-glycine have been found to be the most suitable substrates for determining the activity of ACE with radiochemical assays. The mean-normal values for ACE activity is 25 U/ml; there are no significant differences in ACE activity between different sexes and races, but there is significant decrease in adults. The measurement of ACE activity in sarcoidosis suggests the following results: 1) There is a relationship between the increased SACE and LACE activity and active disease and between normal ACE activity and inactive disease. 2) Normal or decreased ACE activity is useful for therapeutic evaluation of sarcoidosis. 3) Increased SACE activity can be a sensitive parameter for predicting clinical relapse of the disease. An increased SACE activity is found in a wide variety of non-sarcoid granulomatous diseases and non-granulomatous systemic diseases. A decreased SACE and LACE activity is found in non-granulomatous pulmonary diseases such as "Adult Respiratory Distress Syndrome", lung cancer and lung toxicity caused by antineoplastic drugs. Moreover, a low preoperative SACE is associated with poor prognosis in lung cancer and its levels may be useful for predicting clinical relapse of this disorder after operation. Finally, a low SACE activity is found in malignant lymphomas, leukemia and multiple myeloma. A relationship is also found between decreased enzyme activity and a poor prognosis and clinical relapse of these diseases.
...
PMID:[ACE: physiopathology and role in the diagnosis and prognosis of systemic granulomatosis, neoplasms and lung toxicity caused by antineoplastic agents]. 217 27

A 36-year-old man with acute myelogenous leukemia, refractory to the combination chemotherapy, developed fungal infection and acute respiratory distress. Simultaneously, rapid proliferation of leukemic cells was observed in the blood. He was given continuous drip infusion of etoposide (50 mg/day) and Ara-C (20 mg/day) for 18 days. The leukemic cells disappeared from both the blood and the marrow, and complete remission was achieved. There was no adverse effect related to this therapy. The low dose combination chemotherapy with etoposide and Ara-C is safe to be carried out, and could be effective for the patients with refractory leukemia.
...
PMID:[Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia]. 228 79

Twenty-five patients with acute non-lymphoblastic leukemia (ANLL) in first complete remission underwent autologous bone marrow transplantation (ABMT) between March 1984 and March 1988. The high-dose therapy employed included cyclophosphamide followed by total body irradiation (10 Gy), administered as a single dose. The median time from complete remission to ABMT was 5 months (range 2-9 months). Thirteen (52%) patients remain in complete remission 10-51 months (median 25 months) after ABMT and 14-60 months (median 32 months) after achieving complete remission. Causes of death were recurrent leukemia (five patients), parenchymal toxicities (acute respiratory distress syndrome, veno-occlusive disease) (three patients), cerebral haemorrhage (one patient), cerebral aspergillosis (one patient) and viral hepatitis (one patient). Six patients relapsed at a median of 5 months after ABMT (range 4-10 months). In conclusion, this study has resulted in survival data comparable to those of other institutions and the best reported outcomes of conventional chemotherapy.
...
PMID:Autologous unpurged bone marrow transplantation for acute non-lymphoblastic leukaemia in first complete remission. 306 22


1 2 3 4 5 6 7 Next >>